Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen

Tumori

Volumn 96, Issue 1, 2010, Pages 48-53

  Tomasello, Gianluca ^a   Chiesa, Matteo Dalla ^a   Buti, Sebastiano ^a   Brighenti, Matteo ^a   Negri, Federica ^a   Rovere, Rodrigo Kraft ^a   Martinotti, Mario ^a   Buononato, Massimo ^a   Brunelli, Antonio ^a   Lazzarelli, Silvia ^a   Donati, Gianvito ^a   Passalacqua, Rodolfo ^a  

^a CREMONA HOSPITAL   (Italy)

Author keywords

Dose dense chemotherapy; Metastatic gastric cancer; TCF regimen

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INFUSION; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CISPLATIN; DIARRHEA; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VOMITING;

EID: 77950804833     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600108     Document Type: Article

References (25)

1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleigh WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24: 2903-2909, 2006.
2. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, NicolsonM, Hickish T, O'BrienM, Iveson T,WatsonM, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 15: 261-267, 1997.
3. MoehlerM, Lyros O, Gockel I, Galle PR, Lang H:Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol, 14: 3773-3780, 2008.
4. Van CutsemE,MoiseyenkoVM, Tjulandin S,Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24: 4991-4997, 2006.
5. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358: 36-46, 2008.
6. Van CutsemE,Van deVelde C, Roth A, Lordick F, Köhne CH, Cascinu S, Aapro M: Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer, 44: 182-194, 2008.
7. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: theV-325 Study Group. J Clin Oncol, 25: 3205-3209, 2007. (Pubitemid 47333732)
8. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, FodorM, ChaoY,Voznyi E, Awad L,Van Cutsem E: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol, 25: 3210-3216, 2007. (Pubitemid 47325603)
9. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R,Wernli M, LeslieM, Glynne-Jones R,Widmer L, SeymourM, de Braud F: Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol, 25: 3217-3223, 2007.
10. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep, 70: 163-169, 1986.
11. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol, 24:S10-3-S10-10, 1997.
12. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, GradisharWJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 21: 1431-1439, 2003.
13. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, HasencleverD, SchmitzN, Glass B, Rübe C, LoefflerM: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 104: 626-633, 2004. (Pubitemid 38970553)
14. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Collette L: Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer, 42: 50-54, 2006.
15. Cascinu S, Scartozzi M, Labianca R, Catalano V, Silva RR, Barni S, Zaniboni A, D'Angelo A, Salvagni S, Martignoni G, Beretta GD, Graziano F, Berardi R, FranciosiV:High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer, 90: 1521-1525, 2004.
16. Cascinu S, Labianca R, Alessandroni P, Marcellini M, Silva RR, Pancera G, Testa E, Martignoni G, Barni S, Frontini L, Zaniboni A, Luporini G, Cellerino R, Catalano G: Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report fromthe Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol, 15: 3313-3319, 1997.
17. Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I; Italian Group for the Study of Digestive Tract Cancer, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst, 99: 601-607, 2007. (Pubitemid 47073541)
18. de Gramont A, Bosset JF,Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, François E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol, 15: 808-815, 1997.
19. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol, 20: 727-731, 2002.
20. Green MD, Koelbl H, Baselga J, Galid A, GuillemV, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ: A randomized doubleblind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol, 14: 29-35, 2003.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,Verweij J,Van GlabbekeM, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92: 205-216, 2000.
22. Hryniuk WM, Goodyear M: The calculation of received dose intensity. J Clin Oncol, 8: 1935-1937, 1990.
23. Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, BornerMM, Goldhirsch A, de Braud F: 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol, 15: 759-764, 2004.
24. Ajani JA, FodorMB, Tjulandin SA,Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol, 23: 5660-5667, 2005.
25. Ajani JA: Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer, 113: 945-955, 2008.